Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction

Simple item page
dc.contributor.authorYe, Xiaofeng
dc.contributor.authorKong, Wen
dc.contributor.authorZafar, Mohammad Ishraq
dc.contributor.authorZeng, Junchao
dc.contributor.authorYang, Rui
dc.contributor.authorChen, Lu-Lu
dc.date.accessioned2020-12-14T13:42:26Z
dc.date.available2020-12-14T13:42:26Z
dc.date.issued2020-08-20
dc.description.abstractVascular endothelial growth factor B (VEGF-B) is a critical metabolic regulator in insulin resistance, and lipid distribution. We intended to ascertain the relationship between circulating VEGF-B and non-alcoholic fatty liver disease (NAFLD) in the general public. We recruited a total of 194 general participants for a routine physical health examination; of these, 84 participants were identified with NAFLD and 110 without NAFLD based on ultrasonographic findings. Homeostasis model assessment of insulin resistance (HOMA-IR), body mass index (BMI), HbA1c, liver function, kidney function, plasma VEGF-B levels and indexes of metabolic syndrome (blood pressure, fasting plasma glucose, fasting lipids) were evaluated. Plasma VEGF-B values were significantly higher in individuals with NAFLD compared to those without NAFLD (P = 0.022), and analysis of covariance confirmed this result. VEGF-B showed a positive correlation with γ-glutamyl transpeptidase (γ-GT) and HOMA-IR in univariate analysis (q = 0.242; P = 0.001; q =0.174; P = 0.019, respectively). Multiple linear regression analysis showed that γ-GT and ALT were independently correlated with VEGF-B even after adjusted for gender and age (q = 0.286; P = 0.01; q =0.237; P = 0.033, respectively). Moreover, plasma VEGF-B showed a powerful correlation with blood pressure and renal dysfunction. Plasma VEGF-B might be a new clinical variable related to NAFLD and could be a proper biomarker for the early detection of hypertension and renal dysfunction. However, further studies with large cohorts’ size are warranted to validate our findings.en
dc.identifier.citationYe, X., Kong, W., Zafar, M. I., Zeng, J., Yang, R. ., & Chen, L.-L. (2020). Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction. EXCLI Journal, 19. 2020, 186-1195. https://doi.org/10.17179/excli2020-2647en
dc.identifier.issn1611-2156
dc.identifier.urihttp://hdl.handle.net/2003/39886
dc.identifier.urihttp://dx.doi.org/10.17877/DE290R-21777
dc.language.isoen
dc.publisherIfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmundde
dc.relation.ispartofseriesEXCLI Journal;Vol. 19. 2020, 1186-1195
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectVascular endothelial growth factor Ben
dc.subjectNon-alcoholic fatty liver diseaseen
dc.subjectBlood pressureen
dc.subjectRenal dysfunctionen
dc.subjectMetabolismen
dc.subject.ddc610
dc.titlePlasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunctionen
dc.typeText
dc.type.publicationtypearticle
dcterms.accessRightsopen access
eldorado.dnb.zdberstkatid2132560-1
eldorado.identifier.urlhttps://doi.org/10.17179/excli2020-2647
eldorado.secondarypublicationtrue

Files

Collections

Original Articles 2020